Michael Owen
Director/Board Member at SAREUM HOLDINGS PLC
Net worth: 727 650 $ as of 2024-03-30
Profile
Michael John Owen founded Kymab Ltd.
in 2010, where he worked as Chief Scientific Officer from 2010 to 2011.
Dr. Owen also currently works at Ossianix, Inc., as Chairman, Sareum Holdings Plc, as Non-Executive Director from 2018, ReNeuron Group Plc, as Independent Non-Executive Director from 2015, ReNeuron Ltd., as Director from 2000, Gammadelta Therapeutics Ltd., as Director from 2016, Avacta Life Sciences Ltd., as Senior Independent Director, The Club Cricket Organisation Ltd., as Non-Executive Director, Ossianix Uk Ltd., as Director, Novalgen Ltd., as Non-Executive Director from 2023, The European Molecular Biology Laboratory, as Member, and European Molecular Biology Organization, as Member.
Dr. Owen also formerly worked at Avacta Group Plc, as Senior Independent Director, Iksuda Therapeutics Ltd., as Director, BliNK Therapeutics Ltd., as Non-Executive Director, BliNK Biomedical SAS, as Director, Zealand Pharma A, as Independent Director from 2012 to 2024, and GSK Plc, as Senior VP & Head-Biopharmaceuticals Research from 2001 to 2010.
Dr. Owen received his undergraduate degree from the University of Oxford and doctorate degree in 1976 from the University of Cambridge.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ZEALAND PHARMA A/S
0.01% | 2023-12-30 | 7,360 ( 0.01% ) | 727 650 $ | 2024-03-30 |
Michael Owen active positions
Companies | Position | Start |
---|---|---|
RENEURON GROUP PLC | Director/Board Member | 2015-12-03 |
SAREUM HOLDINGS PLC | Director/Board Member | 2018-11-12 |
European Molecular Biology Organization | Corporate Officer/Principal | - |
Ossianix Uk Ltd. | Director/Board Member | - |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | Director/Board Member | - |
The Club Cricket Organisation Ltd. | Director/Board Member | - |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | 2016-08-14 |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Director/Board Member | 2000-07-23 |
The European Molecular Biology Laboratory | Corporate Officer/Principal | - |
░░░░░░░░░ ░░░░ | ░░░░░░░░ | - |
Former positions of Michael Owen
Companies | Position | End |
---|---|---|
░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Michael Owen
University of Oxford | Undergraduate Degree |
University of Cambridge | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 5 |
---|---|
SAREUM HOLDINGS PLC | Miscellaneous |
RENEURON GROUP PLC | Health Technology |
GSK PLC | Health Technology |
ZEALAND PHARMA A/S | Health Technology |
AVACTA GROUP PLC | Commercial Services |
Private companies | 12 |
---|---|
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Health Technology |
European Molecular Biology Organization | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | Health Technology |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | Health Technology |
BliNK Therapeutics Ltd.
BliNK Therapeutics Ltd. BiotechnologyHealth Technology BliNK Therapeutics Ltd. is a holding company which produces monoclonal antibodies using a novel platform. The platform technology provides a new way of activating the immune system’s B cells to produce antibodies in response to a specific antigen. The company was founded in 2011 and is headquartered in Marlow, the United Kingdom. | Health Technology |
BliNK Biomedical SAS
BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | Health Technology |
The Club Cricket Organisation Ltd. | |
Ossianix Uk Ltd. | |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Michael Owen